---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026100"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:57:00.505068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Candel: CAN-2409 final phase 2 data shows median OS 31.4 mo vs 12.5 mo in pancreatic cancer

## Summary
- Estimated median overall survival 31.4 months in CAN-2409 arm vs 12.5 months in control (borderline resectable PDAC).
- Three of seven CAN-2409-treated patients still alive at data cut-off (66.0, 63.6, 35.8 months post-enrollment).
- Median survival post-progression was 21.2 months with CAN-2409 vs 7.2 months in control arm.
- No dose-limiting toxicities or pancreatitis; favorable safety profile.
- Company plans to advance CAN-2409 into a larger late-stage randomized trial in PDAC.

## SEC filing metadata
- accession: 0000950170-25-026100
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/0000950170-25-026100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025026100/cadl-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026100
- JSON: https://secwatch.observer/filing/0000950170-25-026100.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.